Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482017 | 1.00 | EPHX2 (0.46) | EPHX2PPARGIDO1KDM4EALDH1A1 | |
| SCHEMBL25377665 | 0.87 | EPHX2 (0.41) | EPHX2PPARGKDM4EALDH1A1POLB | |
| SCHEMBL28170854 | 0.85 | SCN8A (0.52) | EPHX2PPARGIDO1KDM4EALDH1A1 | |
| SCHEMBL18893127 | 0.84 | EPHX2 (0.44) | EPHX2PPARGIDO1POLBSCN8A | |
| SCHEMBL13208315 | 0.83 | BCHE (0.45) | ALDH1A1POLBBCHEACHE | |
| SCHEMBL11621026 | 0.83 | BCHE (0.40) | EPHX2PPARGIDO1ALDH1A1POLB | |
| SCHEMBL13865872 | 0.83 | HDAC4 (0.49) | EPHX2PPARGTACR1SLC6A2SLC6A4 | |
| SCHEMBL26030471 | 0.80 | BCHE (0.43) | ALDH1A1POLBBCHEACHEATM | |
| SCHEMBL3272017 | 0.80 | BCHE (0.55) | KDM4EALDH1A1POLBBCHEACHE | |
| SCHEMBL12153198 | 0.79 | SCN8A (0.49) | EPHX2PPARGIDO1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| WO-2010065085-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | EPHX2 1393/4885PPARG 695/4885IDO1 681/4885 |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | EPHX2 1224/4885PPARG 3136/4885IDO1 1618/4885 |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | EPHX2 3236/4885PPARG 23/4885IDO1 2628/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | EPHX2 2807/4885PPARG 4069/4885IDO1 985/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | EPHX2 3598/4885PPARG 2664/4885IDO1 2749/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | EPHX2 223/4885PPARG 1222/4885IDO1 807/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | EPHX2 1189/4885PPARG 3616/4885IDO1 2003/4885 |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | EPHX2 1393/4885PPARG 695/4885IDO1 681/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | EPHX2 4541/4885PPARG 4337/4885IDO1 981/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | EPHX2 2448/4885PPARG 4274/4885IDO1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.